What is synergy? The Saariselkä agreement revisited

Many biological or chemical agents when combined interact with each other and produce a synergistic response that cannot be predicted based on the single agent responses alone. However, depending on the postulated null hypothesis of non-interaction, one may end up in different interpretations of synergy. Two popular reference models for null hypothesis include the Bliss independence model and the Loewe additivity model, each of which is formulated from different perspectives. During the last century, there has been an intensive debate on the suitability of these synergy models, both of which are theoretically justified and also in practice supported by different schools of scientists. More than 20 years ago, there was a community effort to make a consensus on the terminology one should use when claiming synergy. The agreement was formulated at a conference held in Saariselkä, Finland in 1992, stating that one should use the terms Bliss synergy or Loewe synergy to avoid ambiguity in the underlying models. We review the theoretical relationships between these models and argue that one should combine the advantages of both models to provide a more consistent definition of synergy and antagonism.

[1]  I. Côté,et al.  Quantifying the evidence for ecological synergies. , 2008, Ecology letters.

[2]  N. Sucher,et al.  Searching for synergy in silico, in vitro and in vivo , 2014 .

[3]  Michael Costanzo,et al.  Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.

[4]  D. Culler,et al.  Comparison of methods , 2000 .

[5]  Hans-Georg Breitinger,et al.  Drug Synergy – Mechanisms and Methods of Analysis , 2012 .

[6]  R. Lotan,et al.  Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy , 2007, Journal of biopharmaceutical statistics.

[7]  C. I. Bliss THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[8]  J Jack Lee,et al.  A Generalized Response Surface Model with Varying Relative Potency for Assessing Drug Interaction , 2006, Biometrics.

[9]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[10]  W. Boedeker,et al.  Assessment of the Combined Effects of Substances: The Relationship between Concentration Addition and Independent Action , 1995 .

[11]  Jack N Saddler,et al.  The enhancement of enzymatic hydrolysis of lignocellulosic substrates by the addition of accessory enzymes such as xylanase: is it an additive or synergistic effect? , 2011, Biotechnology for biofuels.

[12]  Liisa Viikari,et al.  Impact of Xylan on Synergistic Effects of Xylanases and Cellulases in Enzymatic Hydrolysis of Lignocelluloses , 2014, Applied Biochemistry and Biotechnology.

[13]  Steven L. Shafer,et al.  Additivity Versus Synergy: A Theoretical Analysis of Implications for Anesthetic Mechanisms , 2008, Anesthesia and analgesia.

[14]  J. Au,et al.  Comparison of methods for evaluating drug-drug interaction. , 2010, Frontiers in bioscience.

[15]  T. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[16]  R. Tallarida,et al.  An Overview of Drug Combination Analysis with Isobolograms , 2006, Journal of Pharmacology and Experimental Therapeutics.

[17]  T. Bollenbach,et al.  Systematic discovery of drug interaction mechanisms , 2015, Molecular systems biology.

[18]  Berenbaum Mc What is synergy? , 1989, Pharmacological reviews.

[19]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[20]  M. Berenbaum What is synergy? , 1989, Pharmacological reviews.

[21]  Ulf Hammerling,et al.  A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses , 2014, Molecular Cancer Therapeutics.

[22]  Chris Sander,et al.  Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.

[23]  Lanju Zhang,et al.  A New Bliss Independence Model to Analyze Drug Combination Data , 2014, Journal of biomolecular screening.

[24]  S. Loewe The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[25]  Carolina Johansson,et al.  A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[26]  C. Townsend,et al.  Reconceptualizing synergism and antagonism among multiple stressors , 2015, Ecology and evolution.

[27]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[28]  Jan M. Rabaey,et al.  Comparison of Methods , 2004 .

[29]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[30]  Lily Eurwilaichitr,et al.  Binding characteristics and synergistic effects of bacterial expansins on cellulosic and hemicellulosic substrates. , 2015, Bioresource technology.

[31]  Gerhard Müller,et al.  CombiTool - A New Computer Program for Analyzing Combination Experiments with Biologically Active Agents , 1999, Comput. Biomed. Res..

[32]  Sarah B. Laskey,et al.  A mechanistic theory to explain the efficacy of antiretroviral therapy , 2014, Nature Reviews Microbiology.

[33]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[34]  Soo-il Lee,et al.  Drug interaction: focusing on response surface models , 2010, Korean journal of anesthesiology.